While TZL in humans is recognized solely as a morphologic variant of PTCL-NOS, TZL in dogs is typically discussed as a distinct entity due to its relatively high prevalence, its unique CD3+ CD5+ CD25+ CD45- immunophenotype, and its indolent clinical course [7]. Here, CD5 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.